Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

697
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
697
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

583
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
583
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.6K
The pathophysiology of pneumonia involves the following steps:
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new anti-inflammatory treatment for bronchiectasis: a viewpoint on optimal dose selection for DPP1 inhibition in clinical practice.

American journal of respiratory and critical care medicine·2026
Same author

Antibiotic dose-response curves can measure antibiotic activity against <i>Mycobacterium abscessus</i> and <i>Mycobacterium peregrinum</i>.

Antimicrobial agents and chemotherapy·2026
Same author

Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial.

Annals of the American Thoracic Society·2026
Same author

Management of nontuberculous mycobacterial Pulmonary disease refractory to guideline-based therapy: A systematic review.

Pulmonology·2026
Same author

Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial.

Respiratory investigation·2026
Same author

Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria.

EBioMedicine·2026
Same journal

Morphotype-specific susceptibility to <i>Neosartorya</i> (<i>Aspergillus</i>) <i>fischeri</i> antifungal protein 2 is associated with an anabolic transcriptional signature in <i>Candida</i>.

Microbiology spectrum·2026
Same journal

High abundance of <i>Stenotrophomonas maltophilia</i> in slaty-backed gull breeding in Northern Japan.

Microbiology spectrum·2026
Same journal

Rhein reduces conjugation of IncFII-type plasmids in <i>Escherichia coli</i> and mitigates the spread of antibiotic resistance genes.

Microbiology spectrum·2026
Same journal

Phenotypic discordance in rifampicin resistance detection among <i>Mycobacterium tuberculosis</i> isolates from China: insights from whole-genome sequencing and a structured literature review.

Microbiology spectrum·2026
Same journal

Identification of protein secretion systems and type III effectors in wood-associated bacteria of the genus <i>Xylophilus</i>.

Microbiology spectrum·2026
Same journal

Intraspecific diversity of <i>Staphylococcus aureus</i> populations isolated from cystic fibrosis respiratory infections.

Microbiology spectrum·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear
09:20

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear

Published on: July 3, 2025

1.4K

Mycobacterium avium Complex Disease.

Charles L Daley1

  • 1Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO 80206.

Microbiology Spectrum
|April 22, 2017
PubMed
Summary
This summary is machine-generated.

Mycobacterium avium complex (MAC) infections are increasing, requiring careful diagnosis and treatment. New strategies are needed to improve outcomes and prevent reinfection.

More Related Videos

Identification of Mycobacterium Species by DNA Microarray Chip Method
06:27

Identification of Mycobacterium Species by DNA Microarray Chip Method

Published on: June 24, 2025

678
Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes
08:34

Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes

Published on: September 27, 2018

9.2K

Related Experiment Videos

Last Updated: Mar 3, 2026

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear
09:20

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear

Published on: July 3, 2025

1.4K
Identification of Mycobacterium Species by DNA Microarray Chip Method
06:27

Identification of Mycobacterium Species by DNA Microarray Chip Method

Published on: June 24, 2025

678
Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes
08:34

Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes

Published on: September 27, 2018

9.2K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Mycobacterium avium complex (MAC) is environmentally ubiquitous, but disease development requires susceptibility, often linked to lung disease or immunosuppression.
  • Pulmonary MAC disease incidence is rising globally, with unclear etiology.
  • MAC isolation from respiratory samples necessitates careful clinical, radiographic, and microbiologic assessment before initiating treatment.

Purpose of the Study:

  • To review the current understanding and management of Mycobacterium avium complex (MAC) infections.
  • To highlight challenges in diagnosis and treatment, and identify areas for future research.

Main Methods:

  • Literature review of existing studies on MAC epidemiology, pathogenesis, diagnosis, and treatment.
  • Synthesis of clinical guidelines and expert recommendations for managing pulmonary and disseminated MAC.

Main Results:

  • Treatment for nodular bronchiectatic MAC typically involves azithromycin, rifampin, and ethambutol.
  • Cavitary MAC may require daily administration of the same regimen, potentially with parenteral aminoglycosides.
  • Disseminated MAC (DMAC) in AIDS patients necessitates HIV control via antiretroviral therapy, alongside macrolides, ethambutol, and possibly rifabutin.

Conclusions:

  • Optimal treatment for MAC disease remains challenging, with suboptimal outcomes necessitating novel therapeutic approaches.
  • Understanding infection sources and prevention strategies is crucial due to high reinfection rates post-cure.